Cholesteryl ester transfer protein. Its role in cardiovascular disease and drug development

Thesis

Cover

Stellingen

Titlepage

Contents

GENERAL INTRODUCTION

CHAPTER 1 De verhoging van het HDL-cholesterol: nieuwe mogelijkheden voor de preventie van hart- en vaatziekten.

PART A The CETP TaqlB polymorphism and cardiovascular disease.

CHAPTER 2 The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the Cholesterol And Recurrent Events study (CARE): no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome.

CHAPTER 3 The cholesteryl ester transfer protein (CETP) TaqIB polymorphism. HDL cholesterol levels. Cardiovascular risk and the efficacy of pravastatin treatment. A meta-analysis of 12,669 individuals.

PART B The CETP TaqlB polymorphism and cardiovascular disease

CHAPTER 4 Cholesteryl ester transfer protein (CETP) concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).

CHAPTER 5 The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.

CHAPTER 6 Cholesteryl ester transfer protein in relation to lipids. Lipoproteins and coronary angiography in patients with type 2 diabetes mellitus, The Diabetes Atheroscierosis Intervention Study (DAIS)

PART C CETP Inhibition

CHAPTER 7 Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor. JTT-705, in humans.

CHAPTER 8 What can we expect from inhibition of CETP activity in the treatment of dyslipidemia?

SUMMARY

GENERAL DISCUSSION

SAMENVATTING

DANKWOORD

CURRICULUM VITAE

Cover